Skip to main content
Premium Trial:

Request an Annual Quote

H3 Biomedicine, Sage Partner on Genomic Profiling Software

NEW YORK (GenomeWeb News) – Cancer biotherapeutics developer H3 Biomedicine said today that it will partner with Sage Bionetworks to develop new software aimed at supporting its efforts to predict human responses to certain drugs.

Cambridge, Mass.-based H3 said the software will couple its genomic and drug data with Sage's predictive modeling and collaborative capabilities to identify and predict associations between specific genetic alterations and drug response.

H3 said that the data and tools created through its partnership with Sage, a nonprofit research organization located on the campus of Seattle's Fred Hutchinson Cancer Research Center, will be freely accessible to other cancer research organizations.

"We hope that making our collaborative results publicly accessible will advance the field of translational research in oncology, ultimately bringing more personalized medicines to patients with many types of cancers, especially those for whom there are limited effective treatment options," H3 President and CEO Markus Warmuth said in a statement.

H3 said that translating cancer genomic data into new drugs is "largely dependent on the systematic genetic and pharmacological profiling of the increasingly large collection of preclinical cancer genomic models." This partnership seeks to produce an analytical pipeline of such genomic profiling data that may help to identify and verify biomarkers of drug response that could help predict individual patients' drug responses.